Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tomaras

Showing results (281-290 of 525) with videos related to

Pageof 53
Sort By:
Elife|September 17, 2021
Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against HIV-1Shida Shangguan, Philip K Ehrenberg, Aviva Geretz, et al.
Plos Pathogens|November 28, 2022
High-density binding to Plasmodium falciparum circumsporozoite protein repeats by inhibitory antibody elicited in mouse with human immunoglobulin repertoireIga Kucharska, Špela Binter, Rajagopal Murugan, et al.
Clinical and Vaccine Immunology : CVI|April 22, 2016
Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year GapGlenda E Gray, Kenneth H Mayer, Marnie L Elizaga, et al.
The Lancet. HIV|October 12, 2019
Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trialGiuseppe Pantaleo, Holly Janes, Shelly Karuna, et al.
Journal of Virology|August 9, 2013
Lack of B cell dysfunction is associated with functional, gp120-dominant antibody responses in breast milk of simian immunodeficiency virus-infected African green monkeysJoshua D Amos, Andrew B Wilks, Genevieve G Fouda, et al.
Nature Communications|February 22, 2019
Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccineSlim Fourati, Susan Pereira Ribeiro, Filipa Blasco Tavares Pereira Lopes, et al.
Nature Communications|August 23, 2019
Repeated semen exposure decreases cervicovaginal SIVmac251 infection in rhesus macaquesShaheed A Abdulhaqq, Melween Martinez, Guobin Kang, et al.
Journal of Virology|May 11, 2012
The development of CD4 binding site antibodies during HIV-1 infectionRebecca M Lynch, Lillian Tran, Mark K Louder, et al.
The Journal of Infectious Diseases|February 25, 2016
Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or PolyphosphazeneRobert J O'Connell, Jean-Louis Excler, Victoria R Polonis, et al.
Plos One|September 2, 2016
Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African ParticipantsGavin Churchyard, Koleka Mlisana, Shelly Karuna, et al.
Pageof 53

Showing results (281-290 of 525) with videos related to

Sort By:
Pageof 53
Elife|September 17, 2021
Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against HIV-1Shida Shangguan, Philip K Ehrenberg, Aviva Geretz, et al.
Plos Pathogens|November 28, 2022
High-density binding to Plasmodium falciparum circumsporozoite protein repeats by inhibitory antibody elicited in mouse with human immunoglobulin repertoireIga Kucharska, Špela Binter, Rajagopal Murugan, et al.
Clinical and Vaccine Immunology : CVI|April 22, 2016
Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year GapGlenda E Gray, Kenneth H Mayer, Marnie L Elizaga, et al.
The Lancet. HIV|October 12, 2019
Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trialGiuseppe Pantaleo, Holly Janes, Shelly Karuna, et al.
Journal of Virology|August 9, 2013
Lack of B cell dysfunction is associated with functional, gp120-dominant antibody responses in breast milk of simian immunodeficiency virus-infected African green monkeysJoshua D Amos, Andrew B Wilks, Genevieve G Fouda, et al.
Nature Communications|February 22, 2019
Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccineSlim Fourati, Susan Pereira Ribeiro, Filipa Blasco Tavares Pereira Lopes, et al.
Nature Communications|August 23, 2019
Repeated semen exposure decreases cervicovaginal SIVmac251 infection in rhesus macaquesShaheed A Abdulhaqq, Melween Martinez, Guobin Kang, et al.
Journal of Virology|May 11, 2012
The development of CD4 binding site antibodies during HIV-1 infectionRebecca M Lynch, Lillian Tran, Mark K Louder, et al.
The Journal of Infectious Diseases|February 25, 2016
Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or PolyphosphazeneRobert J O'Connell, Jean-Louis Excler, Victoria R Polonis, et al.
Plos One|September 2, 2016
Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African ParticipantsGavin Churchyard, Koleka Mlisana, Shelly Karuna, et al.
Pageof 53